

HEAD AND NECK

CHELSEA HOTEL, TORONTO, ON
 ROOM: WREN A&B
 SUNDAY APRIL 29, 2018, 08:00 AM – 02:00 PM

CO-CHAIRS : J. WALDRON & L. SIU
 SENIOR INVESTIGATOR: WENDY PARULEKAR
 STUDY COORDINATOR: MAGDA MONREAL

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To interpret and address, through clinical and translational research, the disease burden associated with head and neck malignancies in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to head and neck malignancies.
- To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials Group or its collaborators.
- To provide a learning environment supportive to new investigators.
- To interpret and apply new clinical trial methodologies in the field of clinical research in Canada.

8:00 am	Welcome	
8:05 am	HN.9- Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC).	K Sultanem/ A Spreafico
8:35 am	HN.10- A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma.	S Bratman
8:55 am	HN.6 Secondary Analyses Update	W Parulekar, J Ringash, J Waldron, L Siu, R Martino
09:10 am	NRG-HN004- Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin. Break	J Waldron

09:35 am	PRO-ACTIVE: Comparing the Effectiveness of Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer	R Martino
10:00 am	Break	
10:15 am	Head and Neck Cancer International Group (HNCIG) Update	J Waldron
10:40 am	Head and Neck Clinical Trials Landscape	W Parulekar J Waldron
10:55 am	Surgical engagement in CCTG Head and Neck Clinical Trials	A Nichols
11:15 am	New Proposals	
11:30 am	Lunch	
12:00 pm	HN.10 (EVADER) Protocol Review	S Bratman
2:00 pm	Meeting Adjourned	